ARDELYX, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ARDELYX, INC. (ARDX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -6.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-19
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -6.10%, a 217.31% decline from fiscal 2024.
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 5.20%, a 5100.00% increase from fiscal 2023.
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 0.10%.
- ARDELYX, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2020 was -0.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -6.10% 10-K · filed 2026-02-19 |
| 2024-12-31 | 5.20% 10-K · filed 2026-02-19 |
| 2023-12-31 | 0.10% 10-K · filed 2026-02-19 |
| 2020-12-31 | -0.10% 10-K · filed 2021-03-08 |
| 2019-12-31 | -0.90% 10-K · filed 2021-03-08 |
| 2018-12-31 | -1.20% 10-K · filed 2021-03-08 |
| 2017-12-31 | -0.80% 10-K · filed 2020-03-06 |
| 2016-12-31 | 0.10% 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |